Novart siRNA therapy is approved by the European Union

"Bad cholesterol" refers to "low-density lipoprotein cholesterol" (LDL-C), which is an important risk factor for cardiovascular disease.
even though statins that lower LDL-C levels are widespread, heart disease remains one of the leading causes of death worldwide.
despite the widespread use of statins, 80 percent of high-risk patients still fail to meet the LDL-C target recommended by the guidelines, and they urgently need more innovative therapies.
as a "first-in-class" siRNA therapy, inclisiran binds to mRNA that encodes the PCSK9 protein, reducing its level through RNA interference and preventing the liver from producing the PCSK9 protein.
the pcSK9 protein inhibits the recovery and reuse of LDL receptors.
, lowering the levels of the PCSK9 protein allows more LDL subjects to return to the surface of liver cells, bind to more LDL, and remove them from the blood.
the European Commission's decision to approve the treatment, based on the results of the ORION clinical development project.
in clinical trials, inclisiran has shown positive results - inclisiran can reduce LDL-C levels by up to 52% in patients who are still unable to meet LDL-C standards after treatment with the highest to-to-dosage statins.
, the clinical results of the project were published in the New England Journal of Medicine.
in a press release, Ms. Marie-France Tschudin, Global President of Novarma Pharmaceuticals, said, "Cardiovascular disease remains the leading cause of death to this day, indicating that the need for innovative therapies is imminent in patients with LDL-C standards."
" as a "first-in-class" drug, inclisiran can effectively and continuously reduce LDL-C levels, in improving ascertic sclerosis (atherosclerosis cardiovascular disease) patient outcomes have great potential.
, several RNAi therapies have been approved worldwide, but most of them are used to treat rare diseases with a smaller number of patients.
approval of Inclisiran shows the importance of RNAi therapy in expanding its therapeutic field and changing the treatment of popular diseases.
the future, we look forward to more innovative therapies for the benefit of global health!